Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Stig Palm
Observed names:
Palm S,
Palm, S.,
Palm, Stig,
S Palm,
S. Palm,
Stig Harald Palm,
Stig, Palm
show all 7
Institution:
University of Gothenburg
Observed institutions:
International Atomic Energy Agency,
Memorial Sloan Kettering Cancer Center,
University of Aberdeen,
Sahlgrenska University Hospital,
International Atomic Energy Agency,
University of Gothenburg
show all 6
ORCID:
0000-0003-4927-3184
Observed ORCID:
0000-0003-4927-3184
OpenAlex ID:
A5033194381
MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy
2010
·
George Sgouros
, John C. Roeske
, et al.
·
Journal of Nuclear Medicine
·
631
PDF
Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab′)2—A Phase I Study
2009
·
Håkan Andersson
, Elin Cederkrantz
, et al.
·
Journal of Nuclear Medicine
·
331
PDF
Astatine-211 based radionuclide therapy: Current clinical trial landscape
2023
·
Per Albertsson
, Tom Bäck
, et al.
·
Frontiers in Medicine
·
117
PDF
Alpha-Particle Emitting Atomic Generator (Actinium-225)-Labeled Trastuzumab (Herceptin) Targeting of Breast Cancer Spheroids
2004
·
Åse M. Ballangrud
, Wei-Hong Yang
, et al.
·
Clinical Cancer Research
·
116
Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure
2020
·
Sture Lindegren
, Per Albertsson
, et al.
·
Cancer Biotherapy and Radiopharmaceuticals
·
110
ICRP Publication 140: Radiological Protection in Therapy with Radiopharmaceuticals
2019
·
Y. Yonekura
, S. Mattsson
, et al.
·
Annals of the ICRP
·
107
PDF
Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.
2003
·
Stig Palm
, Richard M Enmon
, et al.
·
PubMed
·
107
Intraperitoneal α-Emitting Radioimmunotherapy with211At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations
2019
·
Andreas Hallqvist
, Karin Bergmark
, et al.
·
Journal of Nuclear Medicine
·
87
PDF
Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose.
2006
·
Jörgen Elgqvist
, Håkan Andersson
, et al.
·
PubMed
·
86
Therapeutic Efficacy of Astatine-211–Labeled Trastuzumab on Radioresistant SKOV-3 Tumors in Nude Mice
2007
·
Stig Palm
, Tom Bäck
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
83
PDF
Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
2005
·
Jörgen Elgqvist
, Håkan Andersson
, et al.
·
PubMed
·
82
Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior
2019
·
Yana Dekempeneer
, Tom Bäck
, et al.
·
Molecular Pharmaceutics
·
66
Absorbed Doses and Risk Estimates of 211At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients
2015
·
Elin Cederkrantz
, Håkan Andersson
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
64
Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model.
2003
·
Håkan Andersson
, Jörgen Elgqvist
, et al.
·
PubMed
·
64
Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer.
2001
·
H Andersson
, S Palm
, et al.
·
PubMed
·
57
211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
2005
·
Tom Bäck
, Håkan Andersson
, et al.
·
PubMed
·
54
Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab′)2: therapeutic efficacy and myelotoxicity
2006
·
Jörgen Elgqvist
, Håkan Andersson
, et al.
·
Nuclear Medicine and Biology
·
45
Automated astatination of biomolecules – a stepping stone towards multicenter clinical trials
2015
·
Emma Aneheim
, Per Albertsson
, et al.
·
Scientific Reports
·
43
PDF
How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design
2024
·
Ana P. Kiess
, Joseph O'Donoghue
, et al.
·
Journal of Clinical Oncology
·
40
Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab′)2
2006
·
Jörgen Elgqvist
, Håkan Andersson
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
38
Microdosimetry of astatine-211 single-cell irradiation: Role of daughter polonium-211 diffusion
2004
·
Stig Palm
, John L. Humm
, et al.
·
Medical Physics
·
38
In vitro effects of free 211At,211At-albumin and 211At-monoclonal antibody compared to external photon irradiation on two human cancer cell lines.
2000
·
S Palm
, H Andersson
, et al.
·
PubMed
·
36
Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors
2020
·
Tom A. Bäck
, Karin Jennbacken
, et al.
·
EJNMMI Research
·
35
PDF
Ex Vivo Activity Quantification in Micrometastases at the Cellular Scale Using the α-Camera Technique
2013
·
Nicolas Chouin
, Sture Lindegren
, et al.
·
Journal of Nuclear Medicine
·
31
PDF
Positron emission tomography and computed tomographic (PET/CT) imaging for radiation therapy planning in anal cancer: A systematic review and meta-analysis
2018
·
Per Albertsson
, Charlotte Alverbratt
, et al.
·
Critical Reviews in Oncology/Hematology
·
30
Show more works
View as search
Works count:
89
Citation count:
2,833
H-index:
27
I10-index:
40
Year
Topic
Type